Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline Allurion Technologies, Inc. (“Allurion” or the ...

The Company intends to use the net proceeds from the offering and concurrent private placement to fund its clinical pipeline testing ... the Allurion Balloon and GLP-1 therapy on muscle mass ...

"GLP-1, a hormone that occurs naturally in the gut ... is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Adding 5m GLP-1 patients at slightly lower prices or 21m ... the loss of exclusivity of their blockbuster drug is coming soon, but their pipeline is well set up with notable improvements in ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...